Advertisement
Screener

Erasca, Inc. (ERAS) Earnings Per Share (Basic)

2.8 / 5 stars · 68/120 Roast Me

Erasca, Inc. Earnings Per Share (Basic)

Erasca, Inc. (ERAS) reported Earnings Per Share (Basic) of -$0.14 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Income Statement › Earnings Per Share

us-gaap:EarningsPerShareBasic · last filed 2026-08-11

  • Erasca, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.14.
  • Erasca, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.60.
  • Erasca, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.10.
  • Erasca, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.11.
  • Erasca, Inc. earnings per share, basic for fiscal 2025 was -$0.44.
  • Erasca, Inc. earnings per share, basic for fiscal 2024 was -$0.69.
  • Erasca, Inc. earnings per share, basic for fiscal 2023 was -$0.83.
  • Erasca, Inc. earnings per share, basic for fiscal 2022 was -$1.99.
Period endEarnings Per Share, Basic 3 monthEarnings Per Share, Basic 6 monthEarnings Per Share, Basic 9 monthEarnings Per Share, Basic 12 month
2026-06-30-$0.14
10-Q · filed 2026-08-11
-$0.74
10-Q · filed 2026-08-11
-$0.86
derived: net income ÷ weighted average shares · filed 2026-08-11
-$0.97
derived: net income ÷ weighted average shares · filed 2026-08-11
2026-03-31-$0.60
10-Q · filed 2026-05-11
-$0.72
derived: net income ÷ weighted average shares · filed 2026-08-11
-$0.84
derived: net income ÷ weighted average shares · filed 2026-08-11
-$0.96
derived: net income ÷ weighted average shares · filed 2026-08-11
2025-12-31-$0.10
derived: net income ÷ weighted average shares · filed 2026-03-12
-$0.21
derived: net income ÷ weighted average shares · filed 2026-03-12
-$0.33
derived: net income ÷ weighted average shares · filed 2026-08-11
-$0.44
10-K · filed 2026-03-12
2025-09-30-$0.11
10-Q · filed 2025-11-12
-$0.23
derived: net income ÷ weighted average shares · filed 2026-08-11
-$0.34
10-Q · filed 2025-11-12
-$0.45
derived: net income ÷ weighted average shares · filed 2026-08-11
2025-06-30-$0.12
10-Q · filed 2026-08-11
-$0.23
10-Q · filed 2026-08-11
-$0.34
derived: net income ÷ weighted average shares · filed 2026-08-11
-$0.45
derived: net income ÷ weighted average shares · filed 2026-08-11
2025-03-31-$0.11
10-Q · filed 2026-05-11
-$0.22
derived: net income ÷ weighted average shares · filed 2026-08-11
-$0.33
derived: net income ÷ weighted average shares · filed 2026-08-11
-$0.59
derived: net income ÷ weighted average shares · filed 2026-08-11
2024-12-31-$0.11
derived: net income ÷ weighted average shares · filed 2026-03-12
-$0.22
derived: net income ÷ weighted average shares · filed 2026-03-12
-$0.48
derived: net income ÷ weighted average shares · filed 2026-03-12
-$0.69
10-K · filed 2026-03-12
2024-09-30-$0.11
10-Q · filed 2025-11-12
-$0.38
derived: net income ÷ weighted average shares · filed 2025-11-12
-$0.60
10-Q · filed 2025-11-12
-$0.79
derived: net income ÷ weighted average shares · filed 2025-11-12
2024-06-30-$0.29
10-Q · filed 2025-08-12
-$0.53
10-Q · filed 2025-08-12
-$0.74
derived: net income ÷ weighted average shares · filed 2025-11-12
-$0.94
derived: net income ÷ weighted average shares · filed 2025-11-12
2024-03-31-$0.23
10-Q · filed 2025-05-13
-$0.43
derived: net income ÷ weighted average shares · filed 2025-11-12
-$0.63
derived: net income ÷ weighted average shares · filed 2025-11-12
-$0.84
derived: net income ÷ weighted average shares · filed 2025-11-12
2023-12-31-$0.20
derived: net income ÷ weighted average shares · filed 2025-03-20
-$0.40
derived: net income ÷ weighted average shares · filed 2025-03-20
-$0.61
derived: net income ÷ weighted average shares · filed 2025-03-20
-$0.83
10-K · filed 2025-03-20
2023-09-30-$0.20
10-Q · filed 2024-11-12
-$0.41
derived: net income ÷ weighted average shares · filed 2024-11-12
-$0.64
10-Q · filed 2024-11-12
-$1.60
derived: net income ÷ weighted average shares · filed 2024-11-12
2023-06-30-$0.21
10-Q · filed 2024-08-12
-$0.43
10-Q · filed 2024-08-12
-$1.41
derived: net income ÷ weighted average shares · filed 2024-11-12
-$1.72
derived: net income ÷ weighted average shares · filed 2024-11-12
2023-03-31-$0.22
10-Q · filed 2024-05-08
-$1.22
derived: net income ÷ weighted average shares · filed 2024-11-12
-$1.54
derived: net income ÷ weighted average shares · filed 2024-11-12
-$1.85
derived: net income ÷ weighted average shares · filed 2024-11-12
2022-12-31-$1.06
derived: net income ÷ weighted average shares · filed 2024-03-27
-$1.37
derived: net income ÷ weighted average shares · filed 2024-03-27
-$1.68
derived: net income ÷ weighted average shares · filed 2024-03-27
-$1.99
10-K · filed 2024-03-27
2022-09-30-$0.29
10-Q · filed 2023-11-09
-$0.59
derived: net income ÷ weighted average shares · filed 2023-11-09
-$0.90
10-Q · filed 2023-11-09
-$1.15
derived: net income ÷ weighted average shares · filed 2023-11-09
2022-06-30-$0.30
10-Q · filed 2023-08-10
-$0.60
10-Q · filed 2023-08-10
-$0.86
derived: net income ÷ weighted average shares · filed 2023-11-09
-$1.30
derived: net income ÷ weighted average shares · filed 2023-11-09
2022-03-31-$0.31
10-Q · filed 2023-05-15
-$0.56
derived: net income ÷ weighted average shares · filed 2023-11-09
-$1.00
derived: net income ÷ weighted average shares · filed 2023-11-09
-$1.56
derived: net income ÷ weighted average shares · filed 2023-11-09
2021-12-31-$0.26
derived: net income ÷ weighted average shares · filed 2023-03-23
-$0.70
derived: net income ÷ weighted average shares · filed 2023-03-23
-$1.30
derived: net income ÷ weighted average shares · filed 2023-03-23
-$1.85
10-K · filed 2023-03-23
2021-09-30-$0.46
10-Q · filed 2022-11-09
-$1.21
derived: net income ÷ weighted average shares · filed 2022-11-09
-$1.90
10-Q · filed 2022-11-09
2021-06-30-$1.20
10-Q · filed 2022-08-11
-$2.02
10-Q · filed 2022-08-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Veradermics, Inc (MANE)United States$4.839B
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51